Is thromboelastography able to influence management of patients in cardiology and cardiosurgery?

Czech version

Authors: I. Varga ¹; I. Olejárová ²; E. Goncalvesová ¹
Authors‘ workplace: Oddelenie zlyhávania a transplantácie srdca Národného ústavu srdcových a cievnych chorôb, a. s., Bratislava, Slovenská republika, prednostka doc. MU Dr. Eva Goncalvesová, CSc. ¹; Oddelenie anesteziológie a intenzívnej medicíny Národného ústavu srdcových a cievnych chorôb, a. s., Bratislava, Slovenská republika, primárka MU Dr. Ingrid Olejárová ²
Published in: Vnitř Lék 2009; 55(11): 1070-1078
Category: Reviews

Overview

Thromboelastography (TEG) is perceived as a non‑specific test of hemostasis. It evaluates the global hemocoagulation, however by some modifications could be its diagnostic potential greater. With new inovations is TEG except more precise analysis of participation of blood components on final coagulation (for example rotational TEG) capable also to assess the antiplatelet drug nonresponsiveness (for example platelet mapping system). It gives more accurate information about prothrombotic conditions than routine laboratory techniques in state of ventricular assist device implantation.

Key words:
thromboelastography – hemocoagulation – platelets – antiplatelet drug nonresponsiveness – ventricular assist device

Sources

1. Harrison P, Keeling D. Clinical tests of platelet function. In: Michelson AD et al (eds). Platelets. 2nd ed. Oxford: Elsevier 2007: 445– 474.

2. Kubisz P et al. Hematológia a transfuziológia. Bratislava, Praha: Grada 2006.

3. Kawasaki J, Katori N, Kodaka M et al. Electron microscopic evaluation of clot morphology during thrombelastography®. Anesth Analg 2004; 99: 1440– 1444.

4. Zillmann A, Luther T, Müller I et al. Platelet‑associated tissue factor contributes to the collagen- triggered activation of blood coagulation. Biochem Biophys Res Commun 2001; 281: 603– 609.

5. Samama CM. Thromboelastography: the next step. Anesth Analg 2001; 92: 563– 564.

6. Hájek R, Zezula R, Fluger I et al. Význam tromboelastografie pro monitorování hemostázy v kardiochirurgii. Interv Akut Kardiol 2005; 4: 224– 228.

7. Hájek R, Růžičková J, Gwozdziewicz M et al. Hodnocení funkce trombocytů během mimotělního oběhu pomocí tromboelastografie. Cardiol 2006; 15: 78– 88.

8. Calatzis A, Haas S, Gödje O et al. Thromboelastographic coagulation monitoring during cardiovascular surgery with the ROTEG coagulation analyzer. In: Pifarré R (ed). Management of bleeding in cardiovascular surgery. Philadelphia: Hanley&Belfus 1999: 215– 226.

9. Cox D, Fitzgerald D. Monitoring antiplatelet therapy. In: Gresele P, Page C, Fuster V et al (eds). Platelets in thrombotic and non‑thrombotic disorders. Cambridge: Cambridge University Press 2002: 471– 484.

10. Royston D, von Kier S. Reduced haemostatic factor transfusion using heparinase- modified thrombelastography during cardiopulmonary bypass. Br J Anaesth 2001; 86: 575– 578.

11. Nydegger U. Transfusion dependency in cardiac surgery – update 2006. Swiss Med Wkly 2006; 136: 781– 788.

12. Cammerer U, Dietrich W, Rampf T et al. The predictive value of modified computerized thromboelastography and platelet function analysis for postoperative blood loss in routine cardiac surgery. Anesth Analg 2003; 96: 51– 57.

13. Vorweg M, Hartmann B, Knüttgen Het al. Management of fulminant fibrinolysis during abdominal aortic surgery. J Cardiothorac Vasc Anesth 2001; 6: 764– 767.

14. Kozek- Langenecker S. Management of massive operative blood loss. Minerva Anestesiol 2007; 73: 401– 415.

15. Warnaar N, Molenaar IQ, Colquhoun SD et al. Intraoperative pulmonary embolism and intracardiac thrombosis complicating liver transplantation: a systematic review. J Thromb Haemost 2008; 6: 297– 302.

16. Kettner SC, Gonano C, Seebach F et al. Endogenous heparin‑like substances significantly impair coagulation in patients undergoing orthotopic liver transplantation. Anesth Analg 1998; 86: 691– 695.

17. Nielsen VG, Crow JP, Mogal A et al. Peroxynitrite decreases hemostasis in human plasma in vitro. Anesth Analg 2004; 9: 21– 26.

18. Mittermayr M, Margreiter J, Velik- Salchner C et al. Effects of protamine and heparin can be detected and easily differentiated by modified thrombelastography (Rotem®): an in vitro study. Br J Anaesth 2005; 95: 310– 316.

19. Fenger- Eriksen C, Anker- Møller E, Heslop J et al. Thrombelastographic whole blood clot formation after ex vivo addition of plasma substitutes: improvements of the induced coagulopathy with fibrinogen concentrate. Br J Anaesth 2005; 94: 324– 329.

20. Ingerslev J, Christiansen K, Calatzis A et al. Management and monitoring of recombinant activated factor VII. Blood Coagul Fibrinolysis 2000; 11 (Suppl 1): S25– S30.

21. Studenčan M, Hulíková M, Pavlíková J. Antiphospholipid syndrome in the background of severe cardiovascular complications in patients hospitalised in the cardiology ward. Cardiol 2004; 13: 359– 364.

22. Hemker HC. Platelet procoagulant activities: the amplification loops between platelets and the plasmatic clotting system. In: Gresele P, Page C, Fuster V et al (eds). Platelets in thrombotic and non‑thrombotic disorders. Cambridge: Cambridge University Press 2002: 381– 392.

23. Artang R, Jensen E, Pedersen F et al. Thrombelastography in healthy volunteers, patients with stable angina and acute chest pain. Thromb Res 2000; 97: 499– 503.

24. Patrono C, Bachmann F, Baigent C et al. Expert consensus document on the Use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the european society of cardiology. Eur Heart J 2004; 25: 166– 181.

25. Hricák V, Murín J, Kamenský G et al. Odporúčania pre používanie klopidogrelu u pacientov s akútnym koronárnym syndrómom, stabilnou angínou pektoris a pri sekundárnej prevencii aterotrombotických príhod. Cardiol 2006; 15: 327– 328.

26. Gitt AK, Betriu A. Antiplatelet therapy in acute coronary syndromes. In: Montalescot G (ed). Goals of effective platelet inhibition. Eur Heart J Suppl 2008; 10 (Suppl A): A4– A12.

27. Gladding P, Webster M, Ormiston J et al. Antiplatelet drug nonresponsiveness. Am Heart J 2008; 155: 591– 599.

28. Gurbel PA, Bliden KP, Guyer K et al. Platelet reactivity in patients and recurrent events post‑stenting. Results of the PREPARE POST‑STENTING study. J Am Coll Cardiol 2005; 46: 1820– 1826.

29. Storey RF. Variability of response to antiplatelet therapy. In: Montalescot G (ed). Goals of effective platelet inhibition. Eur Heart J Suppl 2008; 10 (Suppl A): A21– A27.

30. Craft RM, Chavez JJ, Bresee SJ et al. A novel modification of the Thromboelastograph assay, isolating platelet function, correlates with optical platelet aggregation. J Lab Clin Med 2004; 143: 301– 309.

31. Gurbel PA, Bliden KP, DiChiara J et al. Evaluation of dose‑related effects of aspirin on platelet function. Results from the aspirin‑induced platelet effect (ASPECT) study. Circulation 2007; 115: 3156– 3164.

32. Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thromboelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 2005; 46: 1705– 1709.

33. Caroll RC, Craft RM, Chavez JJ et al. A Thromboelastograph whole blood assay for clinical monitoring of NSAID- insensitive transcellular platelet activation by arachidonic acid. J Lab Clin Med 2005; 146: 30– 35.

34. Craft RM, Chavez JJ, Snider CC et al. Comparison of modified Thrombelastograph and Plateletworks whole blood assays to optical platelet aggregation for monitoring reversal of clopidogrel inhibition in elective surgery patients. J Lab Clin Med 2005; 145: 309– 315.

35. Goldstein D, Zucker M, Pagani FD et al. Rotary ventricular assist devices. In: Frazier OH, Kirklin JK et al (eds). Mechanical circulatory support. Oxford: Elsevier 2006: 77– 104.

36. Goncalvesová E, Hulman M, Olejárová I et al. Iniciálne skúsenosti s implantabilnými mechanickými podporami ľavej komory v programe transplantácie srdca v Národnom ústave srdcových a cievnych chorôb. Cardiol 2008; 17: 101– 108.

37. Miller LW, Pagani FD, Russell SD et al. HeartMate II clinical investigators. Use of continuous- flow device in patients awaiting heart transplantation. N Engl J Med 2007; 357: 885– 896.

38. Reilly MP, Wiegers SE, Cucchiara AJ et al. Frequency, risk factors and clinical outcomes of left ventricular assist device‑associated ventricular thrombus. Am J Cardiol 2000; 86: 1156– 1159.

39. Holman WA, Teitel ER, Itescu S. Biologic barriers to mechanical circulatory support. In: Frazier OH, Kirklin JK et al (eds). Mechanical circulatory support. Oxford: Elsevier 2006: 9– 32.

40. Matsubayashi H, Fastenau DR, McIntyre JA. Changes in platelet activation associated with left ventricular assist system placement. J Heart Lung Transplant 2000; 19: 462– 468.

41. Houël R, Mazoyer E, Kirsch M et al. Resistance to aspirin after external ventricular assist device implantation. J Thorac Cardiovasc Surg 2003; 126: 1636– 1637.

42. Tsukui H, Abla A, Teuteberg JJ et al. Cerebrovascular accidents in patients with a ventricular assist device. J Thorac Cardiovasc Surg 2007; 134: 114– 123.

43. Amir O, Bracey AW, Smart FW et al. A successfull anticoagulation protocol for the first HeartMate® II implantation in United States. Tex Heart Inst J 2005; 32: 399– 401.

44. Fries D, Innerhofer P, Streif W et al. Coagulation monitoring and management of anticoagulation during cardiac assist device support. Ann Thorac Surg 2003; 76: 1593– 1597.

45. Seibel K, Berdat P, Boillat C et al. Hemostasis management in pediatric mechanical circulatory support. Ann Thorac Surg 2008; 85: 1453– 1456.

46. Frazier OH, Gemmato C, Myers TJ et al. Initial clinical experience with the HeartMate® II axial- flow left ventricular assist device. Tex Heart Inst J 2007; 34: 275– 281.

47. Meyer A, Kuehn C, Weidemann J et al. Thrombus formation in a HeartMate II left ventricular assist device. J Thorac Cardiovasc Surg 2008; 135: 203– 204.

48. Rothenburger M, Wilhelm MJ, Hammel D et al. Treatment of thrombus formation associated with the MicroMed DeBakey VAD using recombinant tissue plasminogen activator. Circulation 2002; 106 (2 Suppl 1): I189– I192.

49. Steinlechner B, Dworschak M, Birkenberg B et al. Platelet dysfunction in outpatients with left ventricular assist devices. Ann Thorac Surg 2009; 87: 131– 137.